Rice Hall James & Associates LLC Grows Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Rice Hall James & Associates LLC boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 41.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,371,080 shares of the biopharmaceutical company's stock after purchasing an additional 398,942 shares during the quarter. Rice Hall James & Associates LLC owned about 0.46% of Amicus Therapeutics worth $12,916,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of FOLD. Hazlett Burt & Watson Inc. boosted its position in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 1,569 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 1,884 shares in the last quarter. OLD Second National Bank of Aurora bought a new stake in Amicus Therapeutics during the 3rd quarter valued at $26,000. AlphaCentric Advisors LLC boosted its position in Amicus Therapeutics by 1.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company's stock valued at $2,189,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 2,831 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have issued reports on FOLD shares. Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday. Cantor Fitzgerald reissued an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Stock Up 1.3 %

Shares of Amicus Therapeutics stock traded up $0.12 during trading on Friday, reaching $9.19. The company's stock had a trading volume of 2,603,411 shares, compared to its average volume of 2,290,797. The company has a market cap of $2.75 billion, a price-to-earnings ratio of -51.06, a P/E/G ratio of 1.60 and a beta of 0.61. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company has a 50-day simple moving average of $9.56 and a two-hundred day simple moving average of $10.41. Amicus Therapeutics, Inc. has a 1-year low of $8.78 and a 1-year high of $14.02.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.